Skip to main content

Advertisement

SpringerLink
Log in

Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome

  • Case Report
  • Published:
Modern Rheumatology

Abstract

Hemophagocytic syndrome has been reported to be associated with systemic lupus erythematosus. A 25-year-old woman with systemic lupus erythematosus developed hemophagocytic syndrome that was refractory to the combination therapy with high-dose corticosteroid, cyclosporine, and high-dose intravenous immunoglobulin, and successfully treated with the tumor necrosis factor inhibitor, etanercept. This case report provided the first observation that etanercept may be useful for the treatment of hemophagocytic syndrome associated with systemic lupus erythematosus refractory to conventional therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Imashuku S. Advances in the management of hemophagocytic lymphohistiocytosis. Int J Hematol. 2000;72:1–11.

    PubMed  CAS  Google Scholar 

  2. Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89:4100–3.

    PubMed  CAS  Google Scholar 

  3. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105:1648–51.

    Article  PubMed  CAS  Google Scholar 

  4. Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991;114:387–90.

    PubMed  CAS  Google Scholar 

  5. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750–4.

    Article  PubMed  CAS  Google Scholar 

  6. Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, Spaeth PJ, Neftel KA. Hyperferritinema as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol. 2001;68:4–10.

    Article  PubMed  CAS  Google Scholar 

  7. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, Cho CS, Kim HY, Lee WK, Lee SK. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther. 2004;6:295–302.

    Article  Google Scholar 

  8. Balandraud N, Meynard JB, Auger I, Sovran H, Mugnier B, Reviron D, Roudier J, Roudier C. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 2003;48:1223–8.

    Article  PubMed  CAS  Google Scholar 

  9. Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:865–7.

    PubMed  CAS  Google Scholar 

  10. Henzan T, Nagafuji K, Tsukamoto H, Miyamoto T, Gondo H, Imashuku S, Harada M. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81:59–61.

    Article  PubMed  Google Scholar 

  11. Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006;95:38–41.

    Article  PubMed  Google Scholar 

  12. Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596–601.

    Article  PubMed  Google Scholar 

  13. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403–7.

    Article  PubMed  CAS  Google Scholar 

  14. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579–80.

    Article  PubMed  CAS  Google Scholar 

  15. De Ryche L, Baeten D, Kruithof E, van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005;52:2192–201.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fourth Department of Internal Medicine, Nagoya Higashi Municipal Hospital, 1 Wakamizu, Higashi-ku, Nagoya, 464-8547, Japan

    Nobuyuki Takahashi

  2. Division of Rheumatology, Nagoya City University Hospital, Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Taio Naniwa & Shogo Banno

Authors
  1. Nobuyuki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taio Naniwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shogo Banno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuyuki Takahashi.

About this article

Cite this article

Takahashi, N., Naniwa, T. & Banno, S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol 18, 72–75 (2008). https://doi.org/10.1007/s10165-007-0006-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-007-0006-z

Keywords

Search

Navigation